ED-71 Improves Bone Mass in Ovariectomized Rats by Inhibiting Osteoclastogenesis Through EphrinB2-EphB4-RANKL/OPG Axis

References

• Lane JM, Russell L, Khan SN. Osteoporosis. Clin Orthopaedics Related Res. 2000;372(372):139–150. doi:10.1097/00003086-200003000-00016
   Google Scholar
• Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009;301(5):513–521. doi:10.1001/jama.2009.50
   PubMed Web of Science ®Google Scholar
• Gosset A, Pouillès JM, Trémollieres F. Menopausal hormone therapy for the management of osteoporosis. Best Pract Res Clin Endocrinol Metab. 2021;35(6):101551. doi:10.1016/j.beem.2021.101551
   PubMed Web of Science ®Google Scholar
• Khosla S, Oursler MJ, Monroe DG. Estrogen and the skeleton. Trends Endocrinol Metab. 2012;23(11):576–581. doi:10.1016/j.tem.2012.03.008
   PubMed Web of Science ®Google Scholar
• Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2014;142:155–170. doi:10.1016/j.jsbmb.2013.09.008
   PubMed Web of Science ®Google Scholar
• Shieh A, Ishii S, Greendale GA, et al. Urinary N-telopeptide and rate of bone loss over the menopause transition and early postmenopause. J Bone Miner Res. 2016;31(11):2057–2064. doi:10.1002/jbmr.2889
   PubMed Web of Science ®Google Scholar
• Cauley JA, Danielson ME, Greendale GA, et al. Bone resorption and fracture across the menopausal transition: the study of women’s health across the nation. Menopause. 2012;19(11):1200–1207. doi:10.1097/gme.0b013e31825ae17e
   PubMed Web of Science ®Google Scholar
• Wu H, Hu B, Zhou X, et al. Artemether attenuates LPS-induced inflammatory bone loss by inhibiting osteoclastogenesis and bone resorption via suppression of MAPK signaling pathway. Cell Death Dis. 2018;9(5):498. doi:10.1038/s41419-018-0540-y
   PubMedGoogle Scholar
• Taylor S, Hu R, Pacheco E, et al. Differential time-dependent transcriptional changes in the osteoblast lineage in cortical bone associated with sclerostin antibody treatment in ovariectomized rats. Bone Rep. 2018;8:95–103. doi:10.1016/j.bonr.2018.03.002
   PubMedGoogle Scholar
• Kim JM, Lin C, Stavre Z, et al. Osteoblast-osteoclast communication and bone homeostasis. Cells. 2020;9(9):2073. doi:10.3390/cells9092073
   PubMed Web of Science ®Google Scholar
• Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008;473(2):139–146. doi:10.1016/j.abb.2008.03.018
   PubMed Web of Science ®Google Scholar
• Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007;9(Suppl 1(Suppl 1)):S1. doi:10.1186/ar2165
   PubMedGoogle Scholar
• Martin TJ, Allan EH, Ho PW, et al. Communication between ephrinB2 and EphB4 within the osteoblast lineage. Adv Exp Med Biol. 2010;658:51–60.
   PubMed Web of Science ®Google Scholar
• Takyar FM, Tonna S, Ho PW, et al. EphrinB2/EphB4 inhibition in the osteoblast lineage modifies the anabolic response to parathyroid hormone. J Bone Miner Res. 2013;28(4):912–925. doi:10.1002/jbmr.1820
   PubMed Web of Science ®Google Scholar
• He Y, Sun MM, Zhang GG, et al. Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6(1):425. doi:10.1038/s41392-021-00828-5
   PubMed Web of Science ®Google Scholar
• Huang X, Liu G, Guo J, et al. The PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci. 2018;14(11):1483–1496. doi:10.7150/ijbs.27173
   PubMed Web of Science ®Google Scholar
• Ma Y, Ran D, Zhao H, et al. Cadmium exposure triggers osteoporosis in duck via P2X7/PI3K/AKT-mediated osteoblast and osteoclast differentiation. Sci Total Environ. 2021;750:141638. doi:10.1016/j.scitotenv.2020.141638
   PubMed Web of Science ®Google Scholar
• Zhu M, Shi X, Gong Z, et al. Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner. Pharmacol Res. 2020;158:104868. doi:10.1016/j.phrs.2020.104868
   PubMed Web of Science ®Google Scholar
• Reid IR, Billington EO. Drug therapy for osteoporosis in older adults. Lancet. 2022;399(10329):1080–1092. doi:10.1016/S0140-6736(21)02646-5
   PubMed Web of Science ®Google Scholar
• LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10):2049–2102.
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Murayama E, Ochi K, et al. Synthetic studies of vitamin D analogues. XIV. Synthesis and calcium regulating activity of vitamin D3 analogues bearing a hydroxyalkoxy group at the 2 beta-position. Chem Pharm Bull. 1993;41(6):1111–1113. doi:10.1248/cpb.41.1111
   PubMed Web of Science ®Google Scholar
• Okano T, Tsugawa N, Masuda S, et al. Regulatory activities of 2 beta-(3-hydroxypropoxy)-1 alpha, 25-dihydroxyvitamin D3, a novel synthetic vitamin D3 derivative, on calcium metabolism. Biochem Biophys Res Commun. 1989;163(3):1444–1449. doi:10.1016/0006-291X(89)91140-6
   PubMed Web of Science ®Google Scholar
• Uchiyama Y, Higuchi Y, Takeda S, et al. ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone. 2002;30(4):582–588. doi:10.1016/S8756-3282(02)00682-8
   PubMed Web of Science ®Google Scholar
• Kubodera N, Tsuji N, Uchiyama Y, et al. A new active vitamin D analog, ED-71, causes increase in bone mass with preferential effects on bone in osteoporotic patients. J Cell Biochem. 2003;88(2):286–289. doi:10.1002/jcb.10346
   PubMed Web of Science ®Google Scholar
• Arifin WN, Zahiruddin WM. Sample size calculation in animal studies using resource equation approach. Malays J Med Sci. 2017;24(5):101–105. doi:10.21315/mjms2017.24.5.11
   PubMed Web of Science ®Google Scholar
• Kou Y, Rong X, Tang R, et al. Eldecalcitol prevented OVX-induced osteoporosis through inhibiting BMSCs senescence by regulating the SIRT1-Nrf2 signal. Front Pharmacol. 2023;14:1067085. doi:10.3389/fphar.2023.1067085
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kou Y, Yang P, et al. ED-71 inhibited osteoclastogenesis by enhancing EphrinB2-EphB4 signaling between osteoclasts and osteoblasts in osteoporosis. Cell Signal. 2022;96:110376. doi:10.1016/j.cellsig.2022.110376
   PubMed Web of Science ®Google Scholar
• Okamura H, Yang D, Yoshida K, et al. Protein phosphatase 2A Cα is involved in osteoclastogenesis by regulating RANKL and OPG expression in osteoblasts. FEBS Lett. 2013;587(1):48–53. doi:10.1016/j.febslet.2012.10.041
   PubMed Web of Science ®Google Scholar
• Wang R, Luo H, Yang D, et al. Osteoblast Jmjd3 regulates osteoclastogenesis via EphB4 and RANKL signalling. Oral Dis. 2023;29(4):1613–1621. doi:10.1111/odi.14160
   PubMed Web of Science ®Google Scholar
• Väänänen HK, Härkönen PL. Estrogen and bone metabolism. Maturitas. 1996;23(Suppl):S65–69. doi:10.1016/0378-5122(96)01015-8
   PubMedGoogle Scholar
• Matsumoto T, Miki T, Hagino H, et al. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2005;90(9):5031–5036. doi:10.1210/jc.2004-2552
   PubMed Web of Science ®Google Scholar
• Zhao F, Guo L, Wang X, et al. Correlation of oxidative stress-related biomarkers with postmenopausal osteoporosis: a systematic review and meta-analysis. Arch Osteoporos. 2021;16(1):4. doi:10.1007/s11657-020-00854-w
   PubMed Web of Science ®Google Scholar
• Arthur A, Gronthos S. Eph-Ephrin signaling mediates cross-talk within the bone microenvironment. Front Cell Dev Biol. 2021;9:598612. doi:10.3389/fcell.2021.598612
   PubMed Web of Science ®Google Scholar
• Udagawa N, Koide M, Nakamura M, et al. Osteoclast differentiation by RANKL and OPG signaling pathways. J Bone Miner Metab. 2021;39(1):19–26. doi:10.1007/s00774-020-01162-6
   PubMed Web of Science ®Google Scholar
• Yasuda H. Discovery of the RANKL/RANK/OPG system. J Bone Miner Metab. 2021;39(1):2–11. doi:10.1007/s00774-020-01175-1
   PubMed Web of Science ®Google Scholar
• Harada S, Mizoguchi T, Kobayashi Y, et al. Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone. J Bone Miner Res. 2012;27(2):461–473. doi:10.1002/jbmr.555
   PubMed Web of Science ®Google Scholar
• Ge YW, Feng K, Liu XL, et al. The recombinant protein EphB4-Fc changes the ti particle-mediated imbalance of OPG/RANKL via EphrinB2/EphB4 signaling pathway and inhibits the release of proinflammatory factors in vivo. Oxid Med Cell Longev. 2020;2020:1404915. doi:10.1155/2020/1404915
   PubMed Web of Science ®Google Scholar
• Abdurahman A, Li X, Li J, et al. Loading-driven PI3K/Akt signaling and erythropoiesis enhanced angiogenesis and osteogenesis in a postmenopausal osteoporosis mouse model. Bone. 2022;157:116346. doi:10.1016/j.bone.2022.116346
   PubMed Web of Science ®Google Scholar
• Shi X, Zhu M, Gong Z, et al. Homoharringtonine suppresses LoVo cell growth by inhibiting EphB4 and the PI3K/AKT and MAPK/EKR1/2 signaling pathways. Food Chem Toxicol. 2020;136:110960. doi:10.1016/j.fct.2019.110960
   PubMed Web of Science ®Google Scholar
• Zhou M, Xu X, Li J, et al. C-reactive protein perturbs alveolar bone homeostasis: an experimental study of periodontitis and diabetes in the rat. J Clin Periodontol. 2022;49(10):1052–1066. doi:10.1111/jcpe.13667
   PubMed Web of Science ®Google Scholar